Mixofibrosarcoma:un diagnóstico infrecuente

  1. Ulla-Anes, Mariano 1
  2. Palma-Huertas, Elena 1
  3. Pena-Burgos, Manuela 2
  4. Matarranz-del Amo, Mariano 1
  5. Torres-Macho, Juan 1
  1. 1 Servicio de Medicina Interna, Hospital Universitario Infanta Leonor, Madrid, España
  2. 2 Servicio de Anatomía Patológica, Hospital General Universitario Gregorio Marañón, Madrid, España
Zeitschrift:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Datum der Publikation: 2023

Titel der Ausgabe: Revista Española de Casos Clínicos en Medicina Interna

Ausgabe: 8

Nummer: 2

Seiten: 84-87

Art: Artikel

DOI: 10.32818/RECCMI.A8N2A8 DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Ziele für nachhaltige Entwicklung

Zusammenfassung

Myxofibrosarcoma is a mesenchymal tumor typical of elderly patients and it has an infiltrative pattern mainly at local level, which fundamentally requires adequate characterization by nuclear magnetic resonance (MRI) and core needle biopsy (CNB), as well as a multidisciplinary team for its treatment. We present the case of an 85-year-old patient with a painless mass on the right thigh who was admitted to the Internal Medicine unit for initial treatment of a condensing respiratory infection. Finally, after an extensive study, she was diagnosed with myxofibrosarcoma.

Bibliographische Referenzen

  • Vanni S, De Vita A, Gurrieri L, et al. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. Ther Adv Med Oncol. 2022; 14: 1-16. doi: https://doi.org/10.1177/17588359221093973 (últimoacceso abr. 2023).
  • Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016; 25(4): 775-788. doi: https://doi.org/10.1016/j.soc.2016.05.008 (último acceso abr. 2023).
  • Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011; 18(3): 720-725. doi: https://doi.org/10.1245/s10434-010-1341-4 (último acceso abr. 2023).
  • Lawrence W Jr, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987; 205(4): 349-359. doi: https://doi.org/10.1097/00000658-198704000-00003 (último acceso abr. 2023).
  • Christie-Large M, James SL, Tiessen L, Davies AM, Grimer RJ. Imaging strategy for detecting lung metastases at presentation in patients with soft tissue sarcomas. Eur J Cancer. 2008; 44(13): 1841-1845. doi: https://doi.org/10.1016/j.ejca.2008.06.004 (último acceso abr. 2023).
  • Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003; 21(14): 2719-2725. doi: https://doi.org/10.1200/JCO.2003.02.026 (último acceso abr. 2023).
  • Demas BE, Heelan RT, Lane J, Marcove R, Hajdu S, Brennan MF. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol. 1988; 150(3): 615-620. doi: https://doi.org/10.2214/ajr.150.3.615 (último acceso abr. 2023).
  • Strauss DC, Qureshi YA, Hayes AJ, Thway K, Fisher C, Thomas JM. The role of core needle biopsy in the diagnosis of suspected soft tissue tumours. J Surg Oncol. 2010; 102(5): 523-529. doi: https://doi.org/10.1002/jso.21600 (último acceso abr. 2023).
  • Manoso M, Pratt J, Healey JH, Boland PJ, Athanasian EA. Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clinical Orthopaedics and Related Research. 2006; 450: 89–94. doi:https://doi.org/10.1097/01.blo.0000229292.98850.14 (último accesoabr. 2023).
  • Elkrief A, Kazandjian S, Alcindor T. Gemcitabine-containing chemotherapy for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin: a case series. Curr Oncol. 2021; 28(1): 813-817. doi: https://doi.org/10.3390/curroncol28010078 (último acceso ago. 2023).
  • Nakata E, Fujiwara T, Kunisada T, Ito T, Takihira S, Ozaki T. Immunotherapy for sarcomas. Jpn J Clin Oncol. 2021: 51(4): 523-537. doi: https://doi.org/10.1093/jjco/hyab005 (último acceso ago. 2023).
Fuente de los datos: Dialnet